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Telomeres are the ends of linear chromosomes. They cannot be fully replicated by standard polymerases and
are maintained by the ribonucleoprotein telomerase. Telomeres and telomerase stand at a junction of critical
processes underlying chromosome integrity, cancer, and aging, and their importance was recognized by the
2009 Nobel Prize in Physiology or Medicine to Elizabeth Blackburn, Jack Szostak, and Carol Greider. Where
will the field go now?What are the prospects for antitelomerase agents as drugs? Nearly 30 years after Szos-
tak and Blackburn’s pioneering manuscript on telomere ends, the challenges of discovery remain.Cells are packed with nucleic acids: chro-
mosomal DNA, mRNA, tRNA, ribosomal
RNA, and the rapidly expanding world of
other functional RNAs. Each nucleic acid
has a unique chemical personality and
the potential for selective recognition by
designed agents to control almost any
biological process. The 2009 Nobel Prize
in Physiology or Medicine was awarded
for the discovery of one of the most ele-
gant nucleic acid systems inside cells—
telomeres and telomerase.
The End Replication Problem
The ends of linear chromosomes pose
a biological problem. During replication
the lagging strand cannot be fully copied
by standard polymerases. Olovnikov
(1973) and Watson (1972) first pointed
out the implications of this ‘‘end replica-
tion problem.’’ Lacking a means to repli-
cate chromosome ends, chromosomes
would shorten with each cell doubling,
eventually reaching a critical point leading
to cell senescence or death.
Hayflick had previously noted that most
cultured cells could survive only a limited
number of cell divisions and suggested
that finite cellular lifespans might explain
why physiologic function breaks down
as an organism ages (Hayflick and Moor-
head, 1961). It seemed logical that
progressive shortening of chromosome
ends, telomeres, might explain the ‘‘Hay-
flick limit.’’ However, as one question
was answered, another arose: how do
organisms survive from one generation
to the next? Telomeres are long enough
that a given organism might not suffer
the catastrophic consequences of chro-
mosome shortening, but eventually theerosion would take its toll and make life
impossible for the next generation. Both
Olovnikov and Watson suggested that
physiologic systems that maintain telo-
mere length must exist.
Discovery of Telomeres and
Telomerase
The experimental answer to the end repli-
cation problem began to be revealed
when then-postdoctoral fellow Elizabeth
Blackburn and Joseph Gall noted that
chromosome ends from Tetrahymena
thermophila contain the six base se-
quence TTGGGG repeated 20–70 times
(Blackburn and Gall, 1978). Choosing
Tetrahymena as a model organism was
a key factor in the success of this and
subsequent studies because it contains
thousands of chromosomes, providing
an abundance of telomeric material to
analyze.
In 1981, Blackburn, by then an indepen-
dent investigator, collaborated with Jack
Szostak to demonstrate that telomeric
function could be transferred from one
organism (Tetrahymena) to another (Sac-
charomyces cerevisiae) (Szostak and
Blackburn, 1982). This result showed
that some feature of the telomeric
sequence could preserve function from
one organism to the next. Then, in 1985,
Blackburn and Carol Greider identified
an enzymatic activity capable of extend-
ing telomeric sequences (Greider and
Blackburn, 1985). Soon thereafter they
identified the ‘‘terminal transferase’’
activity as belonging to a ribonucleopro-
tein with essential RNA and protein
components and named it ‘‘telomerase’’
(Greider and Blackburn, 1987). The RNAChemistry & Biology 16, December 24, 2009 ªcomponent was found to be complemen-
tary to the sequence of the telomeric
repeat, suggesting that it was acting as
a template for repeat addition (Greider
and Blackburn, 1989).
Telomerase and Cancer
Soon after these discoveries, telomerase
research moved up the evolutionary
ladder as it was established that humans
also have telomeres and that they consist
of the repeated sequence TTAGGG (Moy-
zis et al., 1988). In 1989, Gregg Morin
identified telomerase activity in human
cells (Morin, 1989). His finding was no
small achievement, because human cells
have far fewer telomeres than Tetrahy-
mena and much lower levels of telome-
rase. Morin hypothesized that immortal
cultured human cell lines would express
telomerase, and developed methods for
purifying telomerase activity. Like the
Tetrahymena enzyme, the human enzyme
appeared to be a ribonucleoprotein. In
a tantalizing glimpse of the explosion of
research activity soon to follow, telome-
rase activity was identified in ovarian
tumor cells, but not in isogenic nonmalig-
nant cells, suggesting that telomerase
reactivation might be linked to cancer
cell proliferation (Counter et al., 1994).
In spite of the obvious importance
of telomerase, only a few manuscripts
appeared before 1995 (Figure 1). The
major reason for this was that levels of
human telomerase are so low that much
effort was needed to obtain sufficient
activity for a handful of assays. Then, in
1994, Shay, Wright, and coworkers devel-
oped a simple PCR-based assay, the
telomeric repeat amplification protocol2009 Elsevier Ltd All rights reserved 1219
Figure 1. The Number of Publications in PubMed Citing the Word
‘‘Telomerase’’ and the Year in which They Were Published
Data from 2009 are through October 20, 2009.
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the ability to detect telome-
rase activity (Kim et al.,
1994). An example of using
TRAP to measure the effec-
tiveness of an inhibitor of telo-
merase activity is shown in
Figure 2A. With TRAP, only a
few cells were needed to
quantitate activity. It was now
possible to ask, on a massive
scale, how telomerase acti-
vity correlated with the occur-
rence of human cancer.
Shay and colleagues used
TRAP to show that telome-
rase activity could be de-
tected in almost all immortal
cell lines and cancer biopsies,
but not in mortal cells or
normal tissues (Kim et al.,1994). In one of the first examples of
the power of telomerase measurement
for clinical investigations, TRAP revealed
that neuroblastoma samples lacking telo-
merase activity were associated with
a favorable clinical prognosis (Hiyama
et al., 1995), demonstrating the potential
for telomerase activity to be used as a clin-
ical marker.
The impact of the combination of basic
science and technical breakthroughs is
readily apparent, with publications men-
tioning ‘‘telomerase’’ increasing dramati-
cally during the mid-1990s (Figure 1).
Telomerase activity had been observed
in greater than 90% of patient samples
from a wide range of different cancers
(Shay et al., 2001). Telomerase activity
was also observed in proliferative stem
cells and germ cells (Mantell and Greider,
1994; Broccoli et al., 1995), consistent
with the requirement that these cells
maintain chromosome length over many
cell divisions or, in the case of germ cells,
from one generation of an organism to the
next.
Telomerase: A Target for Inhibitor
Development
Unlike normal cells, cancerous cells must
divide indefinitely to populate a mass suf-
ficiently large and aggressive to threaten
a patient. In the absence of a mechanism
for fully replicating telomeres, cancer
would be self-limiting or would require
development of an alternate mechanism
for maintaining the integrity of their chro-
mosomes. The observation of telomerase1220 Chemistry & Biology 16, December 24,activity in cancerous tissues provided an
explanation for how cancer cells can
proliferate indefinitely.
Telomerase activity is not always re-
quired for cellular immortality. A relatively
small number of immortal cell lines have
been identified that do not express telo-
merase activity but maintain telomere
length by alternative pathways that
depend on recombination (Bryan et al.,
1995; Cesare and Reddel, 2008). The
existence of these cell lines suggests
that some cancer cells might not require
telomerase activity, but reactivation of
telomerase appears to be much more
common.
The belief that telomerase activity was
critically important for sustained cancer
cell proliferation led to the hypothesis
that agents that inhibit telomerase activity
might cause the telomeres of cancer cells
to erode and limit their proliferation.
Successful antitelomerase drugs would
act by a mechanism different from exist-
ing cancer drugs, potentially providing
a valuable new tool for treating cancer
(Shay and Keith, 2008; Harley, 2008).
This hypothesis also predicted that
antitelomerase agents would not kill cells
immediately. Instead, they would cause
steady telomere shortening until a critical
point was reached. In contrast to most
existing drugs, where effects are noted
soon after administration, the antiprolifer-
ative effects of antitelomerase drugs
might occur after weeks or months of
continuous treatment. The potential for
a lag between initiating treatment and2009 ª2009 Elsevier Ltd All rights reservedobserving efficacy is a central
consideration for understand-
ing the challenges of telome-
rase as an anticancer target.
The expected lag between
initial dosing and decreased
cell proliferation leads to the
expectation that telomerase
inhibitors would not be useful
drugs when used to treat
primary tumors because the
tumor might become danger-
ously advanced before drug-
induced telomere shortening
could reduce cancer cell pro-
liferation. Instead, it is more
likely that telomerase inhibi-
tors would be used to prevent
cancer recurrence or treat
secondary cancers that arise
after treatment with existingdrugs. It is also unlikely that telomerase
inhibitors would be used alone. Instead,
they will probably be an adjuvant therapy
that compounds the effects of antiproli-
ferative agents that act through other
mechanisms.
Biological studies provided support for
this hypothesis that inhibiting telomerase
would have an antiproliferative effect.
Expression of a mutated inactive protein
component of telomerase was used to
reduce telomerase activity in cells (Hahn
et al., 1999; Zhang et al., 1999). As pre-
dicted, in the absence of telomerase
activity, telomeres grew progressively
shorter and cell proliferation was de-
creased. The effects of telomerase acti-
vity were also examined in knockout
mice lacking telomerase RNA (mTR/).
Mice have relatively long telomeres, and
for six generations few phenotypes were
observed (Blasco et al., 1997). Eventually,
however, more severe phenotypes were
observed and succeeding generations
became less viable (Lee et al., 1998).
Efforts to develop synthetic telomerase
inhibitors encountered several obstacles:
(1) purified human telomerase was not
available in large quantities, making
screening for inhibitors more cumber-
some; (2) until relatively recently (Gillis
et al., 2008; Sekaran et al., 2009), no
high-resolution structural information was
available, complicating structure-based
design strategies; (3) telomerase is a
polymerase, and inhibitors would need
to be selective for its inhibition relative
to other cellular polymerases; and (4) as
Figure 2. Typical Data from Assays of Telomerase Activity
Demonstrating the Effects of Inhibiting Telomerase
(A) TRAP assay showing inhibition of telomerase activity in C4(2)b cells treated
with complementary 20-methoxyethyl RNA inhibitor ISIS24691 or noncomple-
mentary oligomer ISIS125628 (Canales et al., 2006). Concentration of oligomer
is mM, and compound was delivered into cells in the absence of transfection
reagent. Measurements were in duplicate or quadruplicate. The band at the
bottom of the gel is the internal amplification standard used for quantitation.
(B) Telomere shortening in LNCaP cells measured by the telomere restriction
fragment (TRF) assay. Lane 1: no oligonucleotide added; cells were harvested
after three passages. Lane 2: no oligonucleotide added; cells were harvested
after 17 passages. Lane 3: match oligonucleotide ISIS24691 added for 55
days. Lane 4: mismatch oligonucleotide ISIS125628 added for 55 days.
Lane 5: match oligonucleotide ISIS24691 added for 70 days. Size markers
are shown on the right (Chen et al., 2003). Signal is weaker in the lanes showing
telomere shortening because shortened telomeres have less DNA available for
probe hybridization.
(C) Effect of telomerase inhibition on growth of xenograft tumors in mice (Chen
et al., 2003). LNCaP cells had been treated with match or mismatch oligonu-
cleotide for 21 days prior to implantation. *p < 0.05; **p < 0.001.
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shortening was expected to
yield delayed antiproliferative
effects. Observation of the
key endpoint, cell death,
would be delayed, forcing
assays to be carried out over
weeks or months. As a conse-
quence, two or three months
(or more) might be required
to evaluate a compound and
decide how to proceed with
the next generation of com-
pounds.
Preclinical and Clinical
Development of
Telomerase Inhibitors
One strategy for blocking
telomerase focuses on their
substrate: telomeres. Telo-
meres are G-rich sequences,
TTAGGG in mammals. Struc-
tural studies have shown that
these sequences form four-
stranded G quadruplexes
(Henderson et al., 1987; Par-
kinson et al., 2002). Such
quadruplex structures would
need to unfold before telome-
rase could recognize telo-
mere ends, leading to the
hypothesis that small mole-
cules promoting the forma-
tion of quadruplexes would
block binding to telomerase.
Many different quadruplex-
stabilizing agents have beenidentified (Sun et al., 1997), and several
have been shown to have antiproliferative
effects (Read et al., 2001; Riou et al.,
2002). However, G-rich sequences exist
elsewhere in the genome, and binding to
these sites can cause unexpected effects
(Siddiqui-Jain et al., 2002). Another
obstacle is the inherent difficulty of
designing a planar compound with suffi-
ciently selective intercalation into G quad-
ruplexes relative to the vast amounts
of duplex chromosomal DNA. Advances
in the field have slowed over the past
five years, indicating that the obstacles
confronting the development of potent,
highly selective G-quadruplex-interacting
agents have yet to be overcome.
Another strategy is to use oligonucleo-
tides that are complementary to the
RNA component of telomerase (Figure 2).
To help elongate telomeres, this RNAcomponent must be accessible to binding
by telomere ends. It is logical that it
should also be accessible to binding by
synthetic oligonucleotides and that such
binding should block interactions with
telomeres and inhibit telomerase function.
Two oligonucleotides are approved drugs
and other promising candidates are
advancing through clinical trials (Corey,
2007), suggesting that nucleic acids are
a feasible option for clinical development
of antitelomerase agents.
In 1996, my laboratory showed that
single-stranded peptide nucleic acid
(PNA) oligomers (Figure 3) that are com-
plementary to the template regions of the
telomerase RNA subunit could inhibit
telomerase activity in cancer cell extracts
(Norton et al., 1996). Inhibition was both
potent and sequence specific. Rather
than function like a standard antisenseChemistry & Biology 16, December 24, 2009 ª2009 Elsevioligomer to degrade RNA or
block translation, the olig-
omer acts like an enzyme
inhibitor to block the telome-
rase active site. It is likely
that the effectiveness of anti-
telomerase oligomers is due
to their simple and direct
mechanism of action.
We observed that PNAs,
20-O-methyl, 20-methoxyethyl,
and locked nucleic acid (LNA)
oligomers could be intro-
duced into cells and inhibit
intracellular telomerase (Her-
bert et al., 1999; Shammas
et al., 1999; Chen et al.,
2002, 2003; Elayadi et al.,
2002). The oligonucleotides
caused telomeres to gradually
shorten (Figure 2B). Effects
were observed most rapidly
in cells with short telomeres
and more slowly in cells with
longer telomeres. 20-O-me-
thoxyethyl oligomers slowed
tumor growth both in xeno-
graft tumors (Figure 2C) (Chen
et al., 2003) and in an ortho-
topic intraosseous prostate
cancer model upon systemic
administration (Li et al., 2009).
The potency and selectivity
of oligonucleotides as telo-
merase inhibitors encour-
aged their development as
drugs. Similar to the develop-
ment of any oligonucleotidedrug, the challenge was to identify oligo-
nucleotide chemistry with optimal phar-
macological properties. Geron Corpora-
tion chose to focus on the development
of oligomers containing phosphothioami-
date backbones and, working with the
Shay laboratory, demonstrated potent
inhibition of telomerase (Herbert et al.,
2002). Administration of antitelomerase
phosphoramidate oligonucleotides in a
mouse xenograft model of prostate
cancer suppressed tumor growth (Asai
et al., 2003).
Most researchers working with thera-
peutic oligonucleotides had assumed
that they could not efficiently enter cul-
tured cells in the absence of transfection
reagent. Antitelomerase phosphorami-
date oligomers, however, were potent
inhibitors in the absence of transfec-
tion reagent (Herbert et al., 2002). Thiser Ltd All rights reserved 1221
Figure 3. Structural Features of PNA and Chemically Modified
Oligonucleotides Used to Inhibit Human Telomerase
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phosphoramidate chemistry
might confer advantages for
cell uptake in vivo, a critical
consideration for further de-
velopment. Excellent cell up-
take was also shown by anti-
telomerase 20-methoxyethyl
oligonucleotides (Chen et al.,
2002). Potent activity in the
absence of transfection agent
by two different oligomer
chemistries reemphasizes the
fact that telomerase is not
a typical cellular RNA target
and may have advantages
for recognition by oligonucle-
otides that will facilitate prog-
ress in the clinic.
Examination of chemical
modifications to improve anti-
telomerase thiophosphorami-
date oligomers continued,
and it was discovered that
addition of a lipid group
further increased potency
inside cells (Herbert et al.,
2005). Lipidated oligonucleo-
tide GRN163L was shown
to reduce tumor growth in
several animal studies (Dik-
men et al., 2005; Harley,
2008). GRN163L is now being
tested in phase I and phaseI/II clinical trials for chronic lymphoproli-
ferative disease, solid tumor malignan-
cies, non-small-cell lung cancer, multiple
myeloma, and breast cancer (http://
www.geron.com). Initial reports suggest
that GRN163, the nonlipidated parent
oligonucleotide, is well tolerated by
patients (Harley, 2008), although efficacy
data have yet to be reported. Recently
disclosed phase I results suggest that lipi-
dated GRN163L is also well tolerated by
patients, with some observation of telo-
merase inhibition in tissue (http://www.
geron.com).
Most of these trials examine adminis-
tration of GRN163L in addition to
standard small-molecule or antibody
chemotherapeutic agents. Because of
the potential lag between the onset of
treatment and critical telomere short-
ening, inhibition of telomerase alone may
not be sufficient. Combination treatments
will also be necessary for most trials
because of the necessity of providing
the best existing care to patients partici-1222 Chemistry & Biology 16, December 24,pating in the trial. Because the mecha-
nisms of action of telomerase inhibitors
and standard antiproliferative agents
differ, it is possible that they might yield
synergistic effects (Shay and Keith, 2008).
Three Decades of Progress
The science of telomerase and telomeres
has come a long way since Elizabeth
Blackburn first began experiments inves-
tigating chromosomal ends. The topic
has drawn in researchers from many
disciplines, including chemistry, struc-
tural biology, cell biology, aging, and
cancer biology. This perspective has
focused on the connection between telo-
merase, cancer, and cancer therapy, but
telomerase/telomeres also play a role in
cellular aging (Aubert and Lansdorp,
2008), and recent work suggests that telo-
merase may play roles that go beyond
telomere maintenance (Cong and Shay,
2008; Maida et al., 2009). Similarly, the
discovery of noncoding transcription at
telomeres (Luke and Lingner, 2009;2009 ª2009 Elsevier Ltd All rights reservedSchoeftner and Blasco, 2009)
suggests that they may be
even more complex than had
been originally imagined. It is
likely that the next 30 years
will yield a steady stream of
new discoveries that pro-
foundly affect our under-
standing of cells and provide
opportunities for developing
novel therapeutics.
Chemistry & Biology
invites your comments on
this topic. Please write to
the editors at chembiol@
cell.com.
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